52:
62:
138:
Currently PTCL is treated similarly to B-cell lymphomas. However, in recent years, scientists have developed techniques to better recognize the different types of lymphomas, such as PTCL. It is now understood that PTCL behaves differently from B-cell lymphomas and therapies are being developed that
775:
760:
555:
Corradini P, Tarella C, Zallio F, et al. (September 2006). "Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation".
1731:
182:
Rodriguez, J.; Gutierrez, A.; Martinez-Delgado, B.; Perez-Manga, G. (2009). "Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets".
1475:
512:
Rodríguez J, Conde E, Gutiérrez A, et al. (July 2007). "Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group".
112:
108:
1029:
700:"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d'Etude des lymphomes de l'Adulte study"
118:
PTCL-NOS, the most common subtype of PTCL, is aggressive and predominantly nodal. There are two morphologic variants: the T-zone lymphoma variant and the lymphoepithelioid cell variant.
1146:
790:
1736:
473:"Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma"
1759:
655:
Deconinck E, Lamy T, Foussard C, et al. (June 2000). "Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial".
1111:
1501:
840:
312:
1191:
140:
1704:
1743:
1289:
1034:
1168:
1269:
1067:
1693:
1367:
921:
371:"Cytologic findings of peripheral T-cell lymphoma (PTCL) with high epitheloid cell content (Lennert's lymphoma) in imprint smear. A case report"
1540:
1359:
910:
1688:
1644:
1264:
1062:
946:
422:"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study"
1535:
122:
T-zone lymphoma is so named for its involvement in a specific area of the lymph node that consists of a dense accumulation of T-cells.
699:
613:
421:
833:
1496:
1726:
1718:
1577:
1455:
1394:
1380:
1274:
1215:
1052:
978:
1800:
1774:
1684:
1634:
1530:
1259:
1043:
1666:
1572:
1555:
1363:
917:
826:
115:) but the relationship of EBV to the development and progression of Epstein-Barr virus-associated PTCL-NOS is unclear.
1607:
1480:
1186:
309:
1522:
231:
Rezk SA, Zhao X, Weiss LM (June 2018). "Epstein - Barr virus - associated lymphoid proliferations, a 2018 update".
77:
1410:
1251:
1173:
93:
1612:
1440:
801:
1078:
1629:
1180:
155:. Novel approaches to the treatment of PTCL in the relapsed or refractory setting are under investigation.
1506:
1485:
1399:
1638:
1228:
1122:
148:
139:
specifically target these types of lymphoma. Currently, however, there are no therapies approved by the
1201:
1024:
126:
1435:
1047:
958:
330:"Immunohistologic analysis of the organization of normal lymphoid tissue and non-Hodgkin's lymphomas"
152:
51:
1235:
1019:
989:
779:
614:"Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma"
1699:
680:
581:
537:
256:
104:
727:
641:
449:
329:
1779:
1449:
1430:
1419:
1209:
1099:
1014:
719:
672:
633:
573:
529:
494:
441:
402:
351:
291:
248:
200:
40:
308:
O’Connor, Owen. Getting the Facts; Peripheral T-Cell
Lymphoma. Retrieved May 19, 2009, from
1805:
1549:
1328:
1196:
1095:
818:
711:
664:
625:
565:
521:
484:
433:
392:
382:
341:
283:
240:
192:
1322:
1317:
1126:
1010:
876:
871:
316:
1769:
795:
397:
370:
784:
1794:
1676:
1375:
1284:
1240:
1057:
931:
668:
525:
196:
144:
684:
585:
541:
260:
1279:
941:
165:
are some of the compounds currently under investigations for the treatment of PTC.
162:
158:
310:
http://www.lymphoma.org/atf/cf/%7B0363CDD6-51B5-427B-BE48-E6AF871ACEC9%7D/PTCL.PDF
244:
806:
113:
Epstein-Barr virus-associated peripheral T cell lymphoma, not otherwise specified
103:
About 30% of PTCL-NOS cases exhibit malignant T cells that are infected with the
953:
715:
80:. Peripheral T-cell lymphoma (PTCL) is defined as a diverse group of aggressive
849:
769:
287:
437:
629:
489:
472:
81:
723:
676:
637:
577:
569:
533:
498:
445:
406:
295:
252:
204:
61:
387:
355:
1764:
1592:
1303:
866:
853:
346:
328:
Stein H, Bonk A, Tolksdorf G, Lennert K, Rodt H, Gerdes J (August 1980).
151:
are commonly offered as the initial therapy. Some patients may receive a
89:
45:
752:
17:
97:
85:
107:(EBV). When associated with EBV, PTCL-NOS is classified as one of the
1312:
764:
274:
Vose JM (October 2008). "Peripheral T-cell non-Hodgkin's lymphoma".
219:
WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues
92:) (see figure for an overview of PTCL subtypes). PTCL is a type of
1135:
1000:
984:
1598:
1492:
1471:
1389:
1131:
1106:
1086:
1082:
969:
887:
882:
822:
698:
Haioun C, Lepage E, Gisselbrecht C, et al. (August 2000).
420:
Reimer P, Rüdiger T, Geissinger E, et al. (January 2009).
1338:
1333:
1223:
612:
Gisselbrecht C, Lepage E, Molina T, et al. (May 2002).
1476:
Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma
109:
Epstein-Barr virus-associated lymphoproliferative diseases
471:
Mercadal S, Briones J, Xicoy B, et al. (May 2008).
100:, and results when T-cells develop and grow abnormally.
84:
that develop from mature-stage white blood cells called
96:(NHL). PTCL specifically affects T-cells rather than
742:
1752:
1717:
1675:
1657:
1621:
1591:
1564:
1519:
1464:
1418:
1409:
1349:
1311:
1302:
1250:
1160:
1121:
1077:
999:
968:
930:
909:
898:
865:
746:
39:
34:
1546:Peripheral T-cell lymphoma not otherwise specified
129:, is rare and generally affects older individuals.
70:Peripheral T-cell lymphoma not otherwise specified
35:Peripheral T-cell lymphoma-Not-Otherwise-Specified
1368:Precursor T acute lymphoblastic leukemia/lymphoma
922:Precursor B acute lymphoblastic leukemia/lymphoma
1112:Nodular lymphocyte predominant Hodgkin lymphoma
1502:Secondary cutaneous CD30+ large-cell lymphoma
834:
8:
1192:Post-transplant lymphoproliferative disorder
1147:immunoproliferative immunoglobulin disorders
1705:Diffuse infiltrative lymphocytosis syndrome
1744:Jessner lymphocytic infiltrate of the skin
1415:
1346:
1308:
1290:Primary cutaneous follicle center lymphoma
1035:Primary cutaneous follicle center lymphoma
906:
895:
862:
841:
827:
819:
743:
50:
31:
488:
396:
386:
345:
125:Lympho-epithelioid lymphoma, also called
1270:Primary cutaneous marginal zone lymphoma
1068:Primary cutaneous marginal zone lymphoma
60:
1732:with bandlike and perivascular patterns
1694:Autoimmune lymphoproliferative syndrome
174:
1541:Enteropathy-associated T-cell lymphoma
7:
1689:X-linked lymphoproliferative disease
1645:Large granular lymphocytic leukemia
1265:Intravascular large B-cell lymphoma
25:
669:10.1046/j.1365-2141.2000.02098.x
526:10.1111/j.1600-0609.2007.00856.x
197:10.1016/j.critrevonc.2008.10.011
1497:CD30+ cutaneous T-cell lymphoma
141:US Food and Drug Administration
1727:Cutaneous lymphoid hyperplasia
1719:Cutaneous lymphoid hyperplasia
1578:Adult T-cell leukemia/lymphoma
1456:Adult T-cell leukemia/lymphoma
1395:Anaplastic large-cell lymphoma
1275:Primary cutaneous immunocytoma
1216:Splenic marginal zone lymphoma
276:Hematol. Oncol. Clin. North Am
1:
1775:Lymphoproliferative disorders
1685:Lymphoproliferative disorders
1635:Extranodal NK-T-cell lymphoma
1507:Lymphomatoid papulosis type A
1486:Lymphomatoid papulosis type B
1400:Lymphomatoid papulosis type A
1260:Diffuse large B-cell lymphoma
245:10.1016/j.humpath.2018.05.020
143:(FDA) specifically for PTCL.
1667:Acute biphenotypic leukaemia
1556:Subcutaneous T-cell lymphoma
1608:Aggressive NK-cell leukemia
1481:Pleomorphic T-cell lymphoma
1187:Lymphomatoid granulomatosis
716:10.1200/JCO.2000.18.16.3025
65:Subtypes of T-cell lymphoma
1822:
88:and natural killer cells (
78:peripheral T-cell lymphoma
861:
288:10.1016/j.hoc.2008.07.010
1760:Hematological malignancy
1613:Blastic NK cell lymphoma
1441:Granulomatous slack skin
1197:Classic Hodgkin lymphoma
1096:Classic Hodgkin lymphoma
438:10.1200/JCO.2008.17.4870
630:10.1200/JCO.2002.02.125
315:April 20, 2009, at the
570:10.1038/sj.leu.2404306
334:J. Histochem. Cytochem
185:Crit Rev Oncol Hematol
94:non-Hodgkin's lymphoma
66:
1639:Angiocentric lymphoma
1229:AIDS-related lymphoma
1053:Splenic marginal zone
730:on September 6, 2012.
644:on September 3, 2012.
490:10.1093/annonc/mdn022
388:10.1186/1742-6413-3-3
149:chemotherapy regimens
64:
1801:Non-Hodgkin lymphoma
1737:with nodular pattern
1436:Pagetoid reticulosis
1048:marginal zone B-cell
369:Daneshbod Y (2006).
347:10.1177/28.8.7003001
153:stem cell transplant
1236:Helicobacter pylori
1063:Nodal marginal zone
990:Hairy cell leukemia
856:and related disease
76:), is a subtype of
1780:Lymphoid leukemias
1700:Leukemoid reaction
1536:Angioimmunoblastic
1202:Burkitt's lymphoma
598:d’Amore F, et al.
282:(5): 997–1005, x.
127:Lennert's lymphoma
105:Epstein-Barr virus
67:
1788:
1787:
1713:
1712:
1653:
1652:
1587:
1586:
1515:
1514:
1431:Mycosis fungoides
1298:
1297:
1156:
1155:
1100:Nodular sclerosis
1015:follicular B cell
816:
815:
452:on August 3, 2012
59:
58:
29:Medical condition
16:(Redirected from
1813:
1550:Lennert lymphoma
1416:
1347:
1309:
1174:Primary effusion
907:
896:
863:
843:
836:
829:
820:
744:
732:
731:
726:. Archived from
695:
689:
688:
652:
646:
645:
640:. Archived from
609:
603:
596:
590:
589:
552:
546:
545:
514:Eur. J. Haematol
509:
503:
502:
492:
468:
462:
461:
459:
457:
448:. Archived from
417:
411:
410:
400:
390:
366:
360:
359:
349:
325:
319:
306:
300:
299:
271:
265:
264:
228:
222:
215:
209:
208:
179:
55:
54:
32:
21:
1821:
1820:
1816:
1815:
1814:
1812:
1811:
1810:
1791:
1790:
1789:
1784:
1748:
1709:
1671:
1659:
1649:
1617:
1596:
1583:
1560:
1521:
1511:
1460:
1405:
1353:
1351:
1326:
1321:
1315:
1294:
1246:
1152:
1129:
1117:
1073:
1011:germinal center
995:
964:
926:
902:
900:
880:
875:
869:
857:
847:
817:
812:
811:
755:
741:
736:
735:
710:(16): 3025–30.
697:
696:
692:
657:Br. J. Haematol
654:
653:
649:
611:
610:
606:
597:
593:
554:
553:
549:
511:
510:
506:
470:
469:
465:
455:
453:
419:
418:
414:
368:
367:
363:
327:
326:
322:
317:Wayback Machine
307:
303:
273:
272:
268:
233:Human Pathology
230:
229:
225:
216:
212:
181:
180:
176:
171:
136:
49:
30:
23:
22:
15:
12:
11:
5:
1819:
1817:
1809:
1808:
1803:
1793:
1792:
1786:
1785:
1783:
1782:
1777:
1772:
1770:Leukemia cutis
1767:
1762:
1756:
1754:
1750:
1749:
1747:
1746:
1741:
1740:
1739:
1734:
1723:
1721:
1715:
1714:
1711:
1710:
1708:
1707:
1702:
1697:
1691:
1681:
1679:
1673:
1672:
1670:
1669:
1663:
1661:
1655:
1654:
1651:
1650:
1648:
1647:
1642:
1625:
1623:
1619:
1618:
1616:
1615:
1610:
1604:
1602:
1589:
1588:
1585:
1584:
1582:
1581:
1568:
1566:
1562:
1561:
1559:
1558:
1553:
1543:
1538:
1533:
1527:
1525:
1517:
1516:
1513:
1512:
1510:
1509:
1504:
1499:
1489:
1488:
1483:
1478:
1468:
1466:
1462:
1461:
1459:
1458:
1450:Sézary disease
1444:
1443:
1438:
1433:
1424:
1422:
1413:
1407:
1406:
1404:
1403:
1397:
1385:
1384:
1381:Prolymphocytic
1371:
1357:
1355:
1344:
1343:
1342:
1336:
1306:
1300:
1299:
1296:
1295:
1293:
1292:
1287:
1282:
1277:
1272:
1267:
1262:
1256:
1254:
1248:
1247:
1245:
1244:
1232:
1220:
1219:
1218:
1206:
1205:
1204:
1199:
1194:
1189:
1177:
1164:
1162:
1158:
1157:
1154:
1153:
1151:
1150:
1141:
1139:
1119:
1118:
1116:
1115:
1103:
1092:
1090:
1075:
1074:
1072:
1071:
1065:
1060:
1055:
1039:
1038:
1032:
1027:
1022:
1006:
1004:
997:
996:
994:
993:
981:
979:Prolymphocytic
975:
973:
966:
965:
963:
962:
950:
937:
935:
928:
927:
925:
915:
913:
904:
893:
892:
891:
859:
858:
848:
846:
845:
838:
831:
823:
814:
813:
810:
809:
798:
787:
772:
756:
751:
750:
748:
747:Classification
740:
739:External links
737:
734:
733:
704:J. Clin. Oncol
690:
647:
624:(10): 2472–9.
618:J. Clin. Oncol
604:
591:
547:
504:
463:
426:J. Clin. Oncol
412:
361:
320:
301:
266:
223:
210:
191:(3): 181–198.
173:
172:
170:
167:
135:
132:
131:
130:
123:
57:
56:
43:
37:
36:
28:
24:
14:
13:
10:
9:
6:
4:
3:
2:
1818:
1807:
1804:
1802:
1799:
1798:
1796:
1781:
1778:
1776:
1773:
1771:
1768:
1766:
1763:
1761:
1758:
1757:
1755:
1751:
1745:
1742:
1738:
1735:
1733:
1730:
1729:
1728:
1725:
1724:
1722:
1720:
1716:
1706:
1703:
1701:
1698:
1695:
1692:
1690:
1686:
1683:
1682:
1680:
1678:
1677:Lymphocytosis
1674:
1668:
1665:
1664:
1662:
1656:
1646:
1643:
1640:
1636:
1632:
1631:
1627:
1626:
1624:
1620:
1614:
1611:
1609:
1606:
1605:
1603:
1600:
1594:
1590:
1579:
1575:
1574:
1570:
1569:
1567:
1563:
1557:
1554:
1551:
1547:
1544:
1542:
1539:
1537:
1534:
1532:
1531:Hepatosplenic
1529:
1528:
1526:
1524:
1518:
1508:
1505:
1503:
1500:
1498:
1494:
1491:
1490:
1487:
1484:
1482:
1479:
1477:
1473:
1470:
1469:
1467:
1463:
1457:
1454:
1453:
1452:
1451:
1448:
1442:
1439:
1437:
1434:
1432:
1429:
1426:
1425:
1423:
1421:
1417:
1414:
1412:
1408:
1401:
1398:
1396:
1392:
1391:
1387:
1386:
1382:
1378:
1377:
1376:prolymphocyte
1373:
1372:
1369:
1365:
1361:
1358:
1356:
1348:
1345:
1340:
1337:
1335:
1332:
1331:
1330:
1324:
1319:
1314:
1310:
1307:
1305:
1301:
1291:
1288:
1286:
1285:Plasmacytosis
1283:
1281:
1278:
1276:
1273:
1271:
1268:
1266:
1263:
1261:
1258:
1257:
1255:
1253:
1249:
1242:
1241:MALT lymphoma
1238:
1237:
1233:
1230:
1226:
1225:
1221:
1217:
1214:
1213:
1212:
1211:
1207:
1203:
1200:
1198:
1195:
1193:
1190:
1188:
1185:
1184:
1183:
1182:
1178:
1175:
1171:
1170:
1166:
1165:
1163:
1159:
1149:
1148:
1143:
1142:
1140:
1137:
1133:
1128:
1124:
1120:
1113:
1109:
1108:
1104:
1101:
1097:
1094:
1093:
1091:
1088:
1084:
1080:
1076:
1069:
1066:
1064:
1061:
1059:
1056:
1054:
1050:
1049:
1045:
1044:marginal zone
1041:
1040:
1036:
1033:
1031:
1028:
1026:
1023:
1021:
1017:
1016:
1012:
1008:
1007:
1005:
1002:
998:
991:
987:
986:
982:
980:
977:
976:
974:
971:
967:
960:
956:
955:
951:
948:
944:
943:
939:
938:
936:
933:
929:
923:
919:
916:
914:
912:
908:
905:
897:
894:
889:
886:
885:
884:
878:
873:
868:
864:
860:
855:
851:
844:
839:
837:
832:
830:
825:
824:
821:
808:
804:
803:
799:
797:
793:
792:
788:
786:
782:
781:
777:
773:
771:
767:
766:
762:
758:
757:
754:
749:
745:
738:
729:
725:
721:
717:
713:
709:
705:
701:
694:
691:
686:
682:
678:
674:
670:
666:
663:(4): 736–42.
662:
658:
651:
648:
643:
639:
635:
631:
627:
623:
619:
615:
608:
605:
602:2006;108:A401
601:
595:
592:
587:
583:
579:
575:
571:
567:
564:(9): 1533–8.
563:
559:
551:
548:
543:
539:
535:
531:
527:
523:
519:
515:
508:
505:
500:
496:
491:
486:
483:(5): 958–63.
482:
478:
474:
467:
464:
451:
447:
443:
439:
435:
432:(1): 106–13.
431:
427:
423:
416:
413:
408:
404:
399:
394:
389:
384:
380:
376:
372:
365:
362:
357:
353:
348:
343:
340:(8): 746–60.
339:
335:
331:
324:
321:
318:
314:
311:
305:
302:
297:
293:
289:
285:
281:
277:
270:
267:
262:
258:
254:
250:
246:
242:
238:
234:
227:
224:
220:
217:Swerdlow SH,
214:
211:
206:
202:
198:
194:
190:
186:
178:
175:
168:
166:
164:
160:
156:
154:
150:
146:
145:Anthracycline
142:
133:
128:
124:
121:
120:
119:
116:
114:
110:
106:
101:
99:
95:
91:
87:
83:
79:
75:
71:
63:
53:
47:
44:
42:
38:
33:
27:
19:
1628:
1571:
1565:By infection
1545:
1446:
1445:
1427:
1388:
1374:
1352:development/
1280:Plasmacytoma
1234:
1222:
1208:
1179:
1167:
1161:By infection
1144:
1105:
1042:
1009:
983:
952:
942:naive B cell
940:
901:development/
800:
789:
774:
759:
728:the original
707:
703:
693:
660:
656:
650:
642:the original
621:
617:
607:
599:
594:
561:
557:
550:
517:
513:
507:
480:
476:
466:
454:. Retrieved
450:the original
429:
425:
415:
378:
374:
364:
337:
333:
323:
304:
279:
275:
269:
236:
232:
226:
218:
213:
188:
184:
177:
163:cerdulatinib
159:Pralatrexate
157:
147:-containing
137:
117:
102:
73:
69:
68:
26:
1447:aggressive:
1420:MF+variants
959:Mantle cell
954:mantle zone
520:(1): 32–8.
375:CytoJournal
1795:Categories
1523:peripheral
1020:Follicular
850:Leukaemias
477:Ann. Oncol
169:References
1658:Lymphoid+
1428:indolent:
1411:Cutaneous
1252:Cutaneous
1030:GCB DLBCL
1025:Burkitt's
854:lymphomas
239:: 18–41.
134:Treatment
82:lymphomas
41:Specialty
1765:leukemia
1323:leukemia
1318:lymphoma
877:leukemia
872:lymphoma
724:10944137
685:38197607
677:10929023
638:12011124
586:22959229
578:16871285
558:Leukemia
542:32509254
534:17598836
499:18303032
446:19029417
407:16460569
313:Archived
296:18954748
261:47010934
253:29885408
205:19056295
90:NK cells
74:PTCL-NOS
46:Oncology
18:PTCL-NOS
1806:T cells
1753:General
1660:myeloid
1622:T or NK
1593:NK cell
947:CLL/SLL
807:D016411
796:M9705/3
456:July 6,
398:1434763
356:7003001
98:B-cells
86:T-cells
1597:(most
1573:HTLV-1
1465:Non-MF
1354:marker
1327:(most
1313:T cell
985:CD11c+
903:marker
881:(most
867:B cell
722:
683:
675:
636:
600:Blood.
584:
576:
540:
532:
497:
444:
405:
395:
354:
294:
259:
251:
221:, 2008
203:
48:
1520:Other
1390:CD30+
1136:CD138
1107:CD20+
1001:CD79a
791:ICD-O
785:202.7
770:C84.4
681:S2CID
582:S2CID
538:S2CID
381:: 3.
257:S2CID
111:(see
1599:CD56
1493:CD30
1472:CD30
1360:TdT+
1304:T/NK
1169:KSHV
1145:see
1132:CD38
1123:PCDs
1087:CD30
1083:CD15
1058:MALT
970:CD22
911:TdT+
888:CD20
883:CD19
802:MeSH
780:9-CM
720:PMID
673:PMID
634:PMID
574:PMID
530:PMID
495:PMID
458:2011
442:PMID
403:PMID
352:PMID
292:PMID
249:PMID
201:PMID
161:and
1630:EBV
1495:+:
1474:-:
1364:ALL
1339:CD8
1334:CD4
1329:CD3
1224:HIV
1210:HCV
1181:EBV
1085:+,
932:CD5
918:ALL
776:ICD
761:ICD
712:doi
665:doi
661:109
626:doi
566:doi
522:doi
485:doi
434:doi
393:PMC
383:doi
342:doi
284:doi
241:doi
193:doi
1797::
1362::
1350:By
1138:+)
1134:+/
1127:PP
1089:+)
1079:RS
899:By
852:,
805::
794::
783::
768::
765:10
718:.
708:18
706:.
702:.
679:.
671:.
659:.
632:.
622:20
620:.
616:.
580:.
572:.
562:20
560:.
536:.
528:.
518:79
516:.
493:.
481:19
479:.
475:.
440:.
430:27
428:.
424:.
401:.
391:.
377:.
373:.
350:.
338:28
336:.
332:.
290:.
280:22
278:.
255:.
247:.
237:79
235:.
199:.
189:71
187:.
1696:)
1687:(
1641:)
1637:/
1633:(
1601:)
1595:/
1580:)
1576:(
1552:)
1548:(
1402:)
1393:(
1383:)
1379:(
1370:)
1366:(
1341:)
1325:)
1320:,
1316:(
1243:)
1239:(
1231:)
1227:(
1176:)
1172:(
1130:(
1125:/
1114:)
1110:(
1102:)
1098:(
1081:(
1070:)
1051:(
1046:/
1037:)
1018:(
1013:/
1003:+
992:)
988:(
972:+
961:)
957:(
949:)
945:(
934:+
924:)
920:(
890:)
879:)
874:,
870:(
842:e
835:t
828:v
778:-
763:-
753:D
714::
687:.
667::
628::
588:.
568::
544:.
524::
501:.
487::
460:.
436::
409:.
385::
379:3
358:.
344::
298:.
286::
263:.
243::
207:.
195::
72:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
